COVID-19 Impact on Global HER-2 Targeted Drugs for Breast Cancer Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by HER-2 Targeted Drugs for Breast Cancer Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Trastuzumab
  • 1.4.3 Pertuzumab
  • 1.4.4 Lapatinib
  • 1.4.5 Neratinib
  • 1.4.6 Trastuzumab Emtansine
  • 1.4.7 Pyrotinib
  • 1.4.8 Other
• 1.5 Market by Application
  • 1.5.1 Global HER-2 Targeted Drugs for Breast Cancer Market Share by Application: 2020 VS 2026
  • 1.5.2 Hospital
  • 1.5.3 Clinic
  • 1.5.4 Drug Center
  • 1.5.5 Other
• 1.6 Coronavirus Disease 2019 (Covid-19): HER-2 Targeted Drugs for Breast Cancer Industry Impact
  • 1.6.1 How the Covid-19 is Affecting the HER-2 Targeted Drugs for Breast Cancer Industry
    • 1.6.1.1 HER-2 Targeted Drugs for Breast Cancer Business Impact Assessment - Covid-19
    • 1.6.1.2 Supply Chain Challenges
    • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  • 1.6.2 Market Trends and HER-2 Targeted Drugs for Breast Cancer Potential Opportunities in the COVID-19 Landscape
  • 1.6.3 Measures / Proposal against Covid-19
    • 1.6.3.1 Government Measures to Combat Covid-19 Impact
    • 1.6.3.2 Proposal for HER-2 Targeted Drugs for Breast Cancer Players to Combat Covid-19 Impact
• 1.7 Study Objectives
• 1.8 Years Considered

2 Global Growth Trends by Regions

• 2.1 HER-2 Targeted Drugs for Breast Cancer Market Perspective (2015-2026)
• 2.2 HER-2 Targeted Drugs for Breast Cancer Growth Trends by Regions
  • 2.2.1 HER-2 Targeted Drugs for Breast Cancer Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 HER-2 Targeted Drugs for Breast Cancer Historic Market Share by Regions (2015-2020)
  • 2.2.3 HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 HER-2 Targeted Drugs for Breast Cancer Market Growth Strategy
  • 2.3.6 Primary Interviews with Key HER-2 Targeted Drugs for Breast Cancer Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top HER-2 Targeted Drugs for Breast Cancer Players by Market Size
  • 3.1.1 Global Top HER-2 Targeted Drugs for Breast Cancer Players by Revenue (2015-2020)
  • 3.1.2 Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global HER-2 Targeted Drugs for Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global HER-2 Targeted Drugs for Breast Cancer Market Concentration Ratio
  • 3.2.1 Global HER-2 Targeted Drugs for Breast Cancer Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by HER-2 Targeted Drugs for Breast Cancer Revenue in 2019
• 3.3 HER-2 Targeted Drugs for Breast Cancer Key Players Head office and Area Served
• 3.4 Key Players HER-2 Targeted Drugs for Breast Cancer Product Solution and Service
• 3.5 Date of Enter into HER-2 Targeted Drugs for Breast Cancer Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global HER-2 Targeted Drugs for Breast Cancer Historic Market Size by Type (2015-2020)
• 4.2 Global HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Type (2021-2026)

5 HER-2 Targeted Drugs for Breast Cancer Breakdown Data by Application (2015-2026)

• 5.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)
• 5.2 Global HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America HER-2 Targeted Drugs for Breast Cancer Market Size (2015-2020)
• 6.2 HER-2 Targeted Drugs for Breast Cancer Key Players in North America (2019-2020)
• 6.3 North America HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
• 6.4 North America HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe HER-2 Targeted Drugs for Breast Cancer Market Size (2015-2020)
• 7.2 HER-2 Targeted Drugs for Breast Cancer Key Players in Europe (2019-2020)
• 7.3 Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
• 7.4 Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)

8 China

• 8.1 China HER-2 Targeted Drugs for Breast Cancer Market Size (2015-2020)
• 8.2 HER-2 Targeted Drugs for Breast Cancer Key Players in China (2019-2020)
• 8.3 China HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
• 8.4 China HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan HER-2 Targeted Drugs for Breast Cancer Market Size (2015-2020)
• 9.2 HER-2 Targeted Drugs for Breast Cancer Key Players in Japan (2019-2020)
• 9.3 Japan HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
• 9.4 Japan HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Size (2015-2020)
• 10.2 HER-2 Targeted Drugs for Breast Cancer Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
• 10.4 Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)

11 India

• 11.1 India HER-2 Targeted Drugs for Breast Cancer Market Size (2015-2020)
• 11.2 HER-2 Targeted Drugs for Breast Cancer Key Players in India (2019-2020)
• 11.3 India HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
• 11.4 India HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America HER-2 Targeted Drugs for Breast Cancer Market Size (2015-2020)
• 12.2 HER-2 Targeted Drugs for Breast Cancer Key Players in Central & South America (2019-2020)
• 12.3 Central & South America HER-2 Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
• 12.4 Central & South America HER-2 Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Roche
  • 13.1.1 Roche Company Details
  • 13.1.2 Roche Business Overview and Its Total Revenue
  • 13.1.3 Roche HER-2 Targeted Drugs for Breast Cancer Introduction
  • 13.1.4 Roche Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020))
  • 13.1.5 Roche Recent Development
• 13.2 Chugai Pharmaceutical
  • 13.2.1 Chugai Pharmaceutical Company Details
  • 13.2.2 Chugai Pharmaceutical Business Overview and Its Total Revenue
  • 13.2.3 Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Introduction
  • 13.2.4 Chugai Pharmaceutical Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
  • 13.2.5 Chugai Pharmaceutical Recent Development
• 13.3 GlaxoSmithKline
  • 13.3.1 GlaxoSmithKline Company Details
  • 13.3.2 GlaxoSmithKline Business Overview and Its Total Revenue
  • 13.3.3 GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Introduction
  • 13.3.4 GlaxoSmithKline Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
  • 13.3.5 GlaxoSmithKline Recent Development
• 13.4 Novartis
  • 13.4.1 Novartis Company Details
  • 13.4.2 Novartis Business Overview and Its Total Revenue
  • 13.4.3 Novartis HER-2 Targeted Drugs for Breast Cancer Introduction
  • 13.4.4 Novartis Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
  • 13.4.5 Novartis Recent Development
• 13.5 Pfizer
  • 13.5.1 Pfizer Company Details
  • 13.5.2 Pfizer Business Overview and Its Total Revenue
  • 13.5.3 Pfizer HER-2 Targeted Drugs for Breast Cancer Introduction
  • 13.5.4 Pfizer Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
  • 13.5.5 Pfizer Recent Development
• 13.6 CANbridge
  • 13.6.1 CANbridge Company Details
  • 13.6.2 CANbridge Business Overview and Its Total Revenue
  • 13.6.3 CANbridge HER-2 Targeted Drugs for Breast Cancer Introduction
  • 13.6.4 CANbridge Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
  • 13.6.5 CANbridge Recent Development
• 13.7 Puma Biotechnology
  • 13.7.1 Puma Biotechnology Company Details
  • 13.7.2 Puma Biotechnology Business Overview and Its Total Revenue
  • 13.7.3 Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Introduction
  • 13.7.4 Puma Biotechnology Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
  • 13.7.5 Puma Biotechnology Recent Development
• 13.8 Hengrui Medicine
  • 13.8.1 Hengrui Medicine Company Details
  • 13.8.2 Hengrui Medicine Business Overview and Its Total Revenue
  • 13.8.3 Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Introduction
  • 13.8.4 Hengrui Medicine Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
  • 13.8.5 Hengrui Medicine Recent Development
• 13.9 Beacon Pharmaceuticals Limited
  • 13.9.1 Beacon Pharmaceuticals Limited Company Details
  • 13.9.2 Beacon Pharmaceuticals Limited Business Overview and Its Total Revenue
  • 13.9.3 Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Introduction
  • 13.9.4 Beacon Pharmaceuticals Limited Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
  • 13.9.5 Beacon Pharmaceuticals Limited Recent Development
• 13.10 Hetero Drugs
  • 13.10.1 Hetero Drugs Company Details
  • 13.10.2 Hetero Drugs Business Overview and Its Total Revenue
  • 13.10.3 Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Introduction
  • 13.10.4 Hetero Drugs Revenue in HER-2 Targeted Drugs for Breast Cancer Business (2015-2020)
  • 13.10.5 Hetero Drugs Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer